Global Humanized Mice Model Market Size By Type (Humanized Mouse Models, Humanized Rat Models), By Application (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), By Region, A...

The Global Humanized Mice Model Market was valued at USD 94.3 million in 2023 and is projected to surpass USD 188.1 million by 2031, growing at a CAGR of 8.9% during the forecast period from 2023 to 2031. Humanized mice models are indispensable in preclinical research due to their ability to mimic human physiological and pathological conditions. They are increasingly used for studying cancer immunotherapy, infectious diseases, autoimmune disorders, and drug metabolism. The rise in demand for personalized medicine and biologics, along with increased R&D investments by pharmaceutical and biotechnology companies, is driving market growth.

Drivers:

1. Rising Demand for Personalized Medicine and Immunotherapy:

The surge in oncology research and development of immunotherapies is accelerating the adoption of humanized mice models. These models offer accurate prediction of human responses to therapeutic agents, making them critical tools in preclinical pipelines.

2. Increasing Biomedical Research Activities:

Academic institutes and pharmaceutical companies are increasingly utilizing humanized mice for research on human-specific diseases and drug reactions. Government and private sector funding are further fueling this trend.

3. Advancements in Genetic Engineering Technologies:

Technological advancements in gene editing tools like CRISPR/Cas9 have improved the efficiency and specificity of human gene integration in mice, enhancing the physiological relevance of these models.

Restraints:

1. Ethical Concerns and Regulatory Hurdles:

Use of animals in research raises ethical issues, and strict regulations governing animal testing can slow down the development and deployment of humanized models.

2. High Cost and Complexity of Model Development:

The creation and maintenance of humanized mice are costly and labor-intensive. Their complexity in breeding and susceptibility to infections pose operational challenges for labs.

Opportunity:

1. Growing Investments in Drug Discovery and Translational Research:

The increasing need to bridge the gap between laboratory findings and clinical outcomes is creating substantial opportunities for the adoption of humanized mice, especially in oncology and immunology research.

2. Expansion in Emerging Markets:

Countries like China and India are rapidly expanding their biomedical research infrastructure. Increased funding and favorable policies are likely to attract global players to these regions.

Market by System Type Insights:

Based on system type, the Genetically Engineered Humanized Mice segment accounted for the largest market share in 2023. These models offer enhanced reproducibility and fidelity for human immune system studies and are widely used in immuno-oncology, infectious disease modeling, and pharmacokinetics.

Market by End-use Insights:

In 2023, Pharmaceutical and Biotechnology Companies held the largest share of the market, driven by their extensive use of humanized mice for drug development and safety assessments. The Academic & Research Institutes segment is also growing rapidly, supported by increasing government funding and collaborative research programs.

Market by Regional Insights:

North America dominated the global market in 2023, supported by advanced research infrastructure, strong funding mechanisms, and the presence of major pharmaceutical companies. However, the Asia-Pacific region is anticipated to witness the fastest growth due to rising investments in biomedical research and favorable government initiatives in China, India, and Japan.

Competitive Scenario:

Leading players in the Global Humanized Mice Model Market include Taconic Biosciences, Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, genOway, Inotiv Inc., Hera BioLabs, Harbour BioMed, Champions Oncology, and Vitalstar Biotechnology. These companies are focusing on expanding their product portfolios, forming strategic partnerships, and investing in research to strengthen their market presence.

Scope of Work – Global Humanized Mice Model Market

Report Metric Details

Market Size (2023) USD 94.3 million

Projected Market Size (2031) USD 188.1 million

CAGR (2023–2031) 8.9%

Key Segments By System Type (Genetically Engineered, Cell-based, CD34+ HSC), By End-use

Growth Drivers Demand for personalized medicine, advances in immunotherapy and drug R&D

Opportunities Rising adoption in emerging markets, technological advancements

Key Market Developments:

March 2024: Charles River Laboratories partnered with a global biopharma firm to expand its humanized mouse model platform focused on immuno-oncology.

January 2024: Taconic Biosciences launched a new line of CD34+ HSC humanized mice tailored for long-term immune system studies.

October 2023: genOway received regulatory approval in Europe for a novel humanized model for autoimmune disease applications.

FAQs:

1) What is the current market size of the Global Humanized Mice Model Market?

The market was valued at USD 94.3 million in 2023.

2) What is the major growth driver of the Global Humanized Mice Model Market?

The growing demand for personalized medicine and immunotherapy is a key growth driver.

3) Which is the largest region during the forecast period in the Global Humanized Mice Model Market?

North America is projected to lead the market throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Humanized Mice Model Market?

The Genetically Engineered Humanized Mice segment held the largest share in 2023.

5) Who are the key market players in the Global Humanized Mice Model Market?

Key players include Taconic Biosciences, Charles River Laboratories, The Jackson Laboratory, and Crown Bioscience.